HemoShear Therapeutics to Present Data From its Drug Discovery Platform for NASH at the American Association for the Study of Liver Diseases Annual Meeting

[Charlottesville, VA – November 9, 2016] HemoShear Therapeutics, LLC, a biotechnology company focused on discovering drugs to treat metabolic disorders with significant unmet patient need, today announced that it will present three posters on its human tissue-based NASH drug discovery platform at the American Association for the Study of Liver Diseases annual meeting (AALSD - also known as “The Liver Meeting”) to be held in Boston on November 11-15, 2016. The presentations demonstrate the physiological relevance of HemoShear’s disease models, their ability to predict human response to known drugs in the clinic, and its computational model of NASH.

 

In a presentation entitled, A Human In Vitro Surrogate System For Studying Non-Alcoholic Steatohepatitis (NASH), HemoShear details the functional and clinical validation of its NASH human liver model. This poster received the Presidential Award at this year’s AASLD meeting, recognizing HemoShear’s outstanding contribution in creating advanced, human-relevant models of this rapidly growing disease.

 

In a presentation entitled, Comparison of Obeticholic Acid and GFT505 (Elafibranor) for Treatment of Non-Alcoholic Steatohepatitis (NASH) in a Human In Vitro Surrogate System, HemoShear compares and contrasts head-to-head the responses observed with the two industry-leading, Phase 3 clinical-stage therapeutics in its NASH model.

 

In a presentation entitled, Genome-scale Metabolic Models Reveal Metabolic Alterations in a Human Surrogate Model of Non-Alcoholic Steatohepatitis (NASH), HemoShear utilizes its bioinformatics expertise to uncover perturbations in metabolic flux in silico models for identifying new disease mechanisms and therapeutic strategies in NASH.

 

In an oral presentation entitled, Developing Personalized Drugs for NAFLD and ALD Treatment, HemoShear’s collaborator, Arun Sanyal, MD, explores the future of precision medicine using examples from HemoShear’s NASH model as a potential platform for personalized treatment of liver diseases now and in the future.

 

In addition to HemoShear’s presentations at The Liver Meeting, HemoShear also announced the acceptance of a manuscript in the Journal of Clinical Investigation Insight describing its NASH model. The publication, entitled Development of an In Vitro Human Liver System for Interrogating Non-Alcoholic Steatohepatitis, describes the development and validation of its human tissue-based NASH model by comparing transcriptomic, lipidomic, and functional responses from the model to those observed clinically in NASH patients.

 

“We are proud to showcase our contributions to understanding the biology of this important global disease,” said Dr. Brian Wamhoff, HemoShear co-founder and Head of Innovation. “Building on our human tissue and computational models of NASH, we are especially excited about new data from our models that compare responses to more than 20 drugs in development by various companies and our own novel targets.”

 

Presentation Details:

 

Presentation Title: Human In Vitro Surrogate System For Studying Non-Alcoholic Steatohepatitis (NASH)

Authors: Feaver RE, Cole BK, Lawson MJ, Figler RA, Dash A, Sanyal A, Wamhoff BR

PRESIDENTIAL AWARD WINNER

Session: Steatohepatitis: Experimental I

Poster Number: 1514

Presentation Date and Time: Sunday November 13, 12:30-2PM

Room: Hall C

 

Presentation Title: Comparison of Obeticholic Acid and GFT505 (Elafibranor) for Treatment of Non-Alcoholic Steatohepatitis (NASH) in a Human In Vitro Surrogate System

Authors: Feaver RE, Cole BK, Lawson MJ, Figler RA, Dash A, Sanyal A, Wamhoff BR

Session: Steatohepatitis: Experimental II

Poster Number: 1576

Presentation Date and Time: Sunday November 13, 12:30-2PM

Room: Hall C

 

Presentation Title: Genome-scale Metabolic Models Reveal Metabolic Alterations in a Human Surrogate Model of Non-Alcoholic Steatohepatitis (NASH)

Authors: Hoang SA, Feaver RE, Cole BK, Lawson MJ, Sanyal A, Figler RA, Dash A, Wamhoff BR

Session: Steatohepatitis: Experimental I

Poster Number: 1527

Presentation Date and Time: Sunday November 13, 12:30-2PM

Room: Hall C

 

Presentation Title: Developing Personalized Drugs for NAFLD and ALD Treatment

Presenter: Sanyal A

Session: NAFLD and ALD in the Era of Integrative OMICS and Precision Medicine Data

Presentation Date and Time: Sunday November 13, 10:25-10:45AM

Room: 302/304

 

Publication: Development of an In Vitro Human Liver System for Interrogating Non-Alcoholic Steatohepatitis

Authors: Feaver RE, Cole BK, Lawson MJ, Hoang SA, Marukian S, Figler RA, Sanyal AJ, Wamhoff BR, Dash A

Journal: Journal of Clinical Investigation Insight, 2016 (In Press)

 

###

 

About HemoShear Therapeutics

HemoShear Therapeutics discovers novel biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need. Our proprietary drug discovery platform, REVEAL-TX™, enables us to create best-in class, biological human disease models to uncover and explain the underlying mechanisms of disease, translate those discoveries into drug candidates, and predict which drug candidates will treat patients successfully.

 

Our current drug discovery programs are focused on organic acidemias, a group of rare genetic metabolic disorders, and nonalcoholic steatohepatitis (NASH), a chronic and rapidly growing global disease. HemoShear's collaborators include major pharma companies and leading medical centers.

 

Contact:

Jeremy Mauldin, Ph.D.

HemoShear Therapeutics

P 434 872 0196

M 434 466 8215

Mauldin@hemoshear.com